FDAnews Drug Daily Bulletin

MAAS BIOLAB RECEIVES FORT DETRICK TECHNOLOGY TRANSFER INITIATIVE GRANT FOR CYCLOSPORIN NEUROPROTECTION

April 26, 2006
A A

The Fort Detrick Technology Transfer Initiative (FDTTI) managed by the Maryland Technology Development Corporation (TEDCO) has awarded $50,000 to Maas BiolAB, LLC to continue development of its cyclosporin neuroprotection products. Funding for the FDTTI is provided by the United States Congress. Maas BiolAB, LLC is developing proprietary cyclosporin formulations for the treatment of battlefield traumatic brain injury and nerve agent exposure.
Genetic Engineering News